Anti-april antibodies, anti-april / baff bispecific antibodies, and preparation and use thereof

By designing anti-APRIL/BAFF bispecific antibodies, the problem of difficulty in targeting both BAFF and APRIL in existing technologies has been solved, achieving effective blocking of the BAFF and APRIL signaling pathways and therapeutic effects.

CN122404554APending Publication Date: 2026-07-17SHENYANG SUNSHINE PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510065714.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-15
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing technologies are difficult to effectively target both BAFF and APRIL, which cannot meet the clinical needs of diseases such as IgA nephropathy, and existing fusion proteins have insufficient blocking effects.

Method used

We developed a bispecific antibody against APRIL/BAFF by designing specific HCDR and LCDR sequences to block the binding of APRIL and BAFF to their receptors and optimized the stability and half-life of the Fc domain.

Benefits of technology

It effectively blocks the BAFF and APRIL signaling pathways, exhibits excellent stability and drug-like properties, and can inhibit B cell activation, making it suitable for the prevention or treatment of autoimmune and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005244246830000101
    Figure BDA0005244246830000101
  • Figure BDA0005244246830000111
    Figure BDA0005244246830000111
  • Figure BDA0005244246830000121
    Figure BDA0005244246830000121
Patent Text Reader

Abstract

本发明提供了一种抗APRIL抗体及抗APRIL / BAFF双特异性抗体，所述双抗包含抗APRIL抗体或其抗原结合片段和抗BAFF抗体或其抗原结合片段。本发明的抗APRIL / BAFF双特异性抗体可同时阻断双配体APRIL和BAFF与BCMA的结合，同时还具备优异的稳定性，为预防或治疗APRIL和 / 或BAFF相关疾病提供了新的解决方案。
Need to check novelty before this filing date? Find Prior Art